Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Depsipeptides
  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes

abstract

  • Depsipeptide therapy can be administered with acceptable short-term toxicity. However, gastrointestinal symptoms and fatigue seem to be treatment-limiting after multiple cycles. Depsipeptide monotherapy has limited clinical activity in unselected AML/MDS patients.

publication date

  • February 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-07-0318

PubMed ID

  • 18245545

Additional Document Info

start page

  • 826

end page

  • 32

volume

  • 14

number

  • 3